Trials / Completed
CompletedNCT00236145
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
A Randomised, Open-label, Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ (Oral Transmucosal Fentanyl Citrate) Titrated According to 2 Regimens in Patients With Cancer and Breakthrough Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Cephalon · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a successful dose of ACTIQ treatment more quickly. The successful ACTIQ dose provides a satisfactory combination of efficacy and tolerability after a single administration, as assessed by the patient.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACTIQ (Oral transmucosal fentanyl citrate) |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2005-08-01
- First posted
- 2005-10-12
- Last updated
- 2013-01-29
Source: ClinicalTrials.gov record NCT00236145. Inclusion in this directory is not an endorsement.